6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice:: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein

被引:171
作者
Edwards, DJ
Fitzsimmons, ME
Schuetz, EG
Yasuda, K
Ducharme, MP
Warbasse, LH
Woster, PM
Schuetz, JD
Watkins, P
机构
[1] Univ Michigan, Ctr Med, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Wayne State Univ, Coll Pharm, Detroit, MI USA
[3] Wayne State Univ, Sch Med, Detroit, MI USA
[4] Univ Montreal, Montreal, PQ, Canada
[5] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN USA
关键词
D O I
10.1016/S0009-9236(99)70102-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: 6',7'-Dihydroxybergamottin is a furanocoumarin that inhibits CYP3A4 and is found in grapefruit juice and Seville orange juice. Grapefruit juice increases the oral bioavailability of many CYP3A4 substrates, including cyclosporine (INN, ciclosporin), but intestinal P-glycoprotein may be a more important determinant of cyclosporine availability. Objectives: To evaluate the contribution of 6',7'-dihydroxybergamottin to the effects of grapefruit juice on cyclosporine disposition and to assess the role of CYP3A4 versus P-glycoprotein in this interaction. Methods: The disposition of oral cyclosporine was compared in healthy subjects after ingestion of water, grapefruit juice, and Seville orange juice. Enterocyte concentrations of CYP3A4 were measured in 2 individuals before and after treatment with Seville orange juice. The effect of 6',7'-dihydroxybergamottin on P-glycoprotein was assessed in vitro. Results: Area under the whole blood concentration-time curve and peak concentration of cyclosporine were increased by 55% and 35%, respectively, with grapefruit juice (P < .05). Seville orange juice had no influence on cyclosporine disposition but reduced enterocyte concentrations of CYP3A4 by an average of 40%. 6',7'-Dihydroxybergamottin did not inhibit P-glycoprotein at concentrations up to 50 mu mol/L, Conclusions: 6',7'-Dihydroxybergamottin is not responsible for the effects of grapefruit juice on cyclosporine. Because the interaction did not occur with Seville orange juice despite reduced enterocyte concentrations of CYP3A4, inhibition of P-glycoprotein activity by other compounds in grapefruit juice may be responsible. Reduced enterocyte CYP3A4 by 6',7'-dihydroxybergamottin could be important for other drugs whose bioavailability is less dependent on P-glycoprotein.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 38 条
[11]   Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction [J].
Fukuda, K ;
Ohta, T ;
Oshima, Y ;
Ohashi, N ;
Yoshikawa, M ;
Yamazoe, Y .
PHARMACOGENETICS, 1997, 7 (05) :391-396
[12]  
GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275
[13]   Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice [J].
He, K ;
Iyer, KR ;
Hayes, RN ;
Sinz, MW ;
Woolf, TF ;
Hollenberg, PF .
CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (04) :252-259
[14]   EFFECT OF ERYTHROMYCIN AND TUMOR NECROSIS FACTOR ON THE DRUG-RESISTANCE OF MULTIDRUG-RESISTANT CELLS - REVERSAL OF DRUG-RESISTANCE BY ERYTHROMYCIN [J].
HOFSLI, E ;
NISSENMEYER, J .
INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (03) :520-525
[15]   PLASMA-CONCENTRATIONS OF TRIAZOLAM ARE INCREASED BY CONCOMITANT INGESTION OF GRAPEFRUIT JUICE [J].
HUKKINEN, SK ;
VARHE, A ;
OLKKOLA, KT ;
NEUVONEN, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (02) :127-131
[16]  
Koenigs LL, 1997, DRUG METAB DISPOS, V25, P1407
[17]   IDENTIFICATION OF RIFAMPIN-INDUCIBLE P450IIIA4 (CYP3A4) IN HUMAN SMALL-BOWEL ENTEROCYTES [J].
KOLARS, JC ;
SCHMIEDLINREN, P ;
SCHUETZ, JD ;
FANG, C ;
WATKINS, PB .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05) :1871-1878
[18]   INTERACTION BETWEEN GRAPEFRUIT JUICE AND MIDAZOLAM IN HUMANS [J].
KUPFERSCHMIDT, HHT ;
HA, HR ;
ZIEGLER, WH ;
MEIER, PJ ;
KRAHENBUHL, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :20-28
[19]   Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing [J].
Lan, LB ;
Ayesh, S ;
Lyubimov, E ;
Pashinsky, I ;
Stein, WD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (02) :181-190
[20]  
LETTERON P, 1986, J PHARMACOL EXP THER, V238, P685